-
Mashup Score: 7"Godfather of Artificial Intelligence" Geoffrey Hinton on the promise, risks of advanced AI - 7 month(s) ago
There’s no guaranteed path to safety as artificial intelligence advances, Geoffrey Hinton, AI pioneer, warns. He shares his thoughts on AI’s benefits and dangers with Scott Pelley.
Source: www.cbsnews.comCategories: Future of Medicine, Latest HeadlinesTweet
-
Mashup Score: 0The PROMISE Minimal Risk Score Improves Risk Classification of Symptomatic Patients With Suspected CAD: - 2 year(s) ago
Abstract Background Guidelines for evaluating patients with suspected coronary artery disease (CAD) recommend pretest probability (PTP) estimation but provide no clear recommendations regarding dia…
Source: JACC: Cardiovascular ImagingCategories: Cardiology News and Journals, Latest HeadlinesTweet-
Improved risk stratification beyond ESC & ACC/AHA guidelines? In this #PROMISE study, 1/3 of >5-15% PTP pts are ⬇️ classified as low risk (<5%) by a novel “PROMISE Minimal Risk Score” for pts in whom #cvCAD #chestpain testing may be deferred. https://t.co/NjlyxT7RJP #JACCIMG https://t.co/6WqwvVQNzL
-
-
Mashup Score: 1Coronary Atherosclerosis, Cardiac Troponin, and Interleukin-6 in Patients With Chest Pain: The PROMISE Trial Results - 2 year(s) ago
Abstract Background Increased inflammation and myocardial injury can be observed in the absence of myocardial infarction or obstructive coronary artery disease (CAD). Objectives The authors determi…
Source: JACC: Cardiovascular ImagingCategories: Expert Picks, Latest HeadlinesTweet-
Inflammation, myocardial injury, non-obstructive #cvCAD & new Tx 🎯? New research led by @CardiacCTGuy from #PROMISE finds that hs-cTn & IL-6 were assoc. w/ detailed characteristics of coronary #atherosclerosis by #YesCCT + ⬆️ risk of #MACE. https://t.co/gSrbB7gOqe #JACCIMG https://t.co/wxfnqFcaNH
-
-
Mashup Score: 3Age-Related Differences in Noninvasive Evaluation of Possible Coronary Artery Disease - 2 year(s) ago
This prespecified analysis of the PROMISE randomized clinical trial determines whether the prognostic utility of anatomic vs functional testing for coronary artery disease varies based on patient age.
Source: jamanetwork.comCategories: Cardiologists, Latest HeadlinesTweet-
7. #PROMISE #SCCT2022 How age is factored into the decision making @JAMANetwork https://t.co/ODrrVPK6hk
-
-
Mashup Score: 1Prognostic Value of Coronary Artery Calcium in the PROMISE Study (Prospective Multicenter Imaging Study for Evaluation of Chest Pain) - 2 year(s) ago
Background:Coronary artery calcium (CAC) is an established predictor of future major adverse atherosclerotic cardiovascular events in asymptomatic individuals. However, limited data exist as to how C
Source: CirculationCategories: Cardiologists, Latest HeadlinesTweet-
@AChoiHeart @ToddVillinesMD @imagingmedsci @ghoshhajra #SCCT2022 @Heart_SCCT This is a great paper on CACS vs Functional testing from #PROMISE @CircAHA https://t.co/IjaNlZGSg6
-
-
Mashup Score: 0Real-World Understanding of the Prevalence of Potentially Targetable DNA Damage Repair Alterations – The PROMISE Registry – Heather Cheng - 2 year(s) ago
Heather Cheng joins Alicia Morgans to discuss the trial in progress poster presented at GU ASCO 2022 on the PROMISE Registry. The goal of the PROMISE registry is to offer genetic testing for men with prostate cancer regardless of the stage of their disease. The registry will recruit over five years, with fifteen years of planned follow-up. Biographies: Heather H. Cheng, MD, PhD, Director,…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet-
Real-world understanding of the prevalence of potentially targetable DNA damage repair alterations. The #PROMISE Registry. @heatherhcheng @UW joins @CaPsurvivorship @DanaFarber to discuss data presented at @ASCO #GU22 on UroToday > https://t.co/w44eyPqjWP @SeattleCCA https://t.co/ODxwWXI0WT
-
-
Mashup Score: 4Real-World Understanding of the Prevalence of Potentially Targetable DNA Damage Repair Alterations – The PROMISE Registry – Heather Cheng - 2 year(s) ago
Heather Cheng joins Alicia Morgans to discuss the trial in progress poster presented at GU ASCO 2022 on the PROMISE Registry. The goal of the PROMISE registry is to offer genetic testing for men with prostate cancer regardless of the stage of their disease. The registry will recruit over five years, with fifteen years of planned follow-up. Biographies: Heather H. Cheng, MD, PhD, Director,…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet-
Real-world understanding of the prevalence of potentially targetable DNA damage repair alterations. The #PROMISE Registry. @heatherhcheng @UW joins @CaPsurvivorship @DanaFarber to discuss data presented at @ASCO #GU22 on UroToday > https://t.co/w44eyPqjWP @SeattleCCA https://t.co/Y6OAysJPu5
-
-
Mashup Score: 0Real-World Understanding of the Prevalence of Potentially Targetable DNA Damage Repair Alterations – The PROMISE Registry – Heather Cheng - 2 year(s) ago
Heather Cheng joins Alicia Morgans to discuss the trial in progress poster presented at GU ASCO 2022 on the PROMISE Registry. The goal of the PROMISE registry is to offer genetic testing for men with prostate cancer regardless of the stage of their disease. The registry will recruit over five years, with fifteen years of planned follow-up. Biographies: Heather H. Cheng, MD, PhD, Director,…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet-
Real-world understanding of the prevalence of potentially targetable DNA damage repair alterations. The #PROMISE Registry. @heatherhcheng @UW joins @CaPsurvivorship @DanaFarber to discuss data presented at @ASCO #GU22 on UroToday > https://t.co/w44eyPqjWP @SeattleCCA https://t.co/KPhNYCy8Fo
-
-
Mashup Score: 1Real-World Understanding of the Prevalence of Potentially Targetable DNA Damage Repair Alterations – The PROMISE Registry – Heather Cheng - 2 year(s) ago
Heather Cheng joins Alicia Morgans to discuss the trial in progress poster presented at GU ASCO 2022 on the PROMISE Registry. The goal of the PROMISE registry is to offer genetic testing for men with prostate cancer regardless of the stage of their disease. The registry will recruit over five years, with fifteen years of planned follow-up. Biographies: Heather H. Cheng, MD, PhD, Director,…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet-
Real-world understanding of the prevalence of potentially targetable DNA damage repair alterations. The #PROMISE Registry. @heatherhcheng @UW joins @CaPsurvivorship @DanaFarber to discuss data presented at @ASCO #GU22 on UroToday > https://t.co/w44eyPqjWP @SeattleCCA https://t.co/HrZIyyCuQc
-
-
Mashup Score: 0Real-World Understanding of the Prevalence of Potentially Targetable DNA Damage Repair Alterations – The PROMISE Registry – Heather Cheng - 2 year(s) ago
Heather Cheng joins Alicia Morgans to discuss the trial in progress poster presented at GU ASCO 2022 on the PROMISE Registry. The goal of the PROMISE registry is to offer genetic testing for men with prostate cancer regardless of the stage of their disease. The registry will recruit over five years, with fifteen years of planned follow-up. Biographies: Heather H. Cheng, MD, PhD, Director,…
Source: UroTodayCategories: Latest Headlines, UrologyTweet-
Real-world understanding of the prevalence of potentially targetable DNA damage repair alterations. The #PROMISE Registry. @heatherhcheng @UW joins @CaPsurvivorship @DanaFarber to discuss data presented at @ASCO #GU22 on UroToday > https://t.co/w44eyPqjWP @SeattleCCA https://t.co/4O7JIuMXjo
-
RT @Shi4Tech: Godfather of #ArtificialIntelligence @geoffreyhinton on the #Promise, #Risks of advanced #AI https://t.co/Q1Z3cpiQnU v/…